Inha University announced on Wednesday that a research team led by Professor Son Se-jin from the Department of Life Sciences has developed a groundbreaking cancer immunotherapy strategy. This innovative approach could potentially treat recurrent and metastatic cancers by harnessing tumors within patients’ bodies.
The team published a comprehensive review in the prestigious journal Signal Transduction and Targeted Therapy (STTT), analyzing the combination therapy strategy of the promising in situ cancer vaccine.
Conventional cancer treatments primarily focus on eliminating visible tumors, falling short in preventing recurrence and metastasis. While personalized cancer vaccines show promise, they’re often hindered by time-consuming and costly production processes.
The in situ cancer vaccine approach leverages the patient’s own tumor as a vaccine.
By inducing cancer cells to die in specific ways, immune cells learn to recognize and remember cancer cell characteristics. This enables them to target not only the original tumor but also potential recurrences and metastases. Essentially, the patient’s tumor becomes its own ‘vaccine material,’ eliminating the need for custom vaccine production.
The study also explored various combination strategies to enhance treatment efficacy.
Researchers examined the potential of combining immune checkpoint inhibitors, chemotherapy, and radiation therapy with immunogenic cell death (ICD), which triggers immune responses as cancer cells die. They presented a comprehensive analysis of these combinations and their potential for clinical application.
The team emphasized the significance of this research in offering a new direction for cancer immunotherapy. It presents the possibility of treating recurrent and metastatic cancers without the complexities of custom vaccine production. They anticipate this approach could make treatment more accessible to patients by reducing production time and costs.
From an economic standpoint, the researchers suggest this strategy could drive innovation in next-generation cancer drug development among domestic pharmaceutical and biotech companies.
Hwang Jin-woo, a student in the integrated master’s and doctoral program in Life Sciences, served as the paper’s first author. Fellow students Baek Joo-won and Choi Hye-bin contributed as co-authors. The paper is titled, Combinatorial in situ cancer vaccines: unlocking broad and enhanced antitumor responses.
STTT is a leading publication in cancer research and signal transduction, with an impressive impact factor of 81.2 according to recent JCR standards, placing it in the top 0.2% of journals in its field.
Professor Son Se-jin stated that this research systematically maps out the development of in situ cancer vaccines through various combination strategies. It points towards more effective approaches in cancer immunotherapy development. It’s committed to continuing the work on innovative cancer immunotherapy platforms.